0.8025
Schlusskurs vom Vortag:
$0.8501
Offen:
$0.826
24-Stunden-Volumen:
508.82K
Relative Volume:
1.13
Marktkapitalisierung:
$53.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-46.12M
KGV:
-0.9286
EPS:
-0.8642
Netto-Cashflow:
$-41.02M
1W Leistung:
-56.62%
1M Leistung:
-44.66%
6M Leistung:
-67.38%
1J Leistung:
-43.88%
Inflarx N V Stock (IFRX) Company Profile
Vergleichen Sie IFRX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
IFRX
Inflarx N V
|
0.8025 | 125.33M | 0 | -46.12M | -41.02M | -0.8642 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
2022-02-28 | Herabstufung | Guggenheim | Buy → Neutral |
2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
2021-03-11 | Hochstufung | Guggenheim | Neutral → Buy |
2020-11-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2020-10-08 | Eingeleitet | H.C. Wainwright | Buy |
2020-06-17 | Eingeleitet | BTIG Research | Buy |
2020-04-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2019-06-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2019-06-05 | Herabstufung | Guggenheim | Buy → Neutral |
2019-06-05 | Herabstufung | JP Morgan | Overweight → Underweight |
2019-06-05 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2019-06-05 | Herabstufung | SunTrust | Buy → Hold |
2019-01-29 | Eingeleitet | Robert W. Baird | Outperform |
2018-12-10 | Eingeleitet | Credit Suisse | Outperform |
2018-07-13 | Eingeleitet | BMO Capital Markets | Outperform |
2018-06-28 | Eingeleitet | Raymond James | Outperform |
2018-06-28 | Eingeleitet | SunTrust | Buy |
2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Inflarx N V Aktie (IFRX) Neueste Nachrichten
InflaRx (NASDAQ:IFRX) Price Target Cut to $3.00 by Analysts at Oppenheimer - Defense World
InflaRx stock rating cut, price target slashed to $2 by Raymond James - Investing.com Nigeria
InflaRx (IFRX) Maintains Outperform Rating, Price Target Adjusted | IFRX Stock News - GuruFocus
IFRX Price Target Cut as Phase 3 Trial Halts | IFRX Stock News - GuruFocus
Oppenheimer Adjusts Price Target on InflaRx N.V to $3 From $6, Maintains Outperform Rating - marketscreener.com
Raymond James Downgrades InflaRx to Outperform From Strong Buy, Price Target is $13 - marketscreener.com
Guggenheim maintains $10 target on Inflarx despite study halt - Investing.com Australia
InflaRx (IFRX) Faces Downgrade as Phase 3 Trial Halts | IFRX Sto - GuruFocus
InflaRx (IFRX) Faces Downgrade as Phase 3 Trial Halts | IFRX Stock News - GuruFocus
InflaRx downgraded to Outperform from Strong Buy at Raymond James - TipRanks
Top Midday Decliners - marketscreener.com
Crude Oil Gains 2%; Macy's Lowers Earnings Forecast - Benzinga
Guggenheim maintains $10 target on Inflarx despite study halt By Investing.com - Investing.com India
InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease - Benzinga
PG rating: Inflarx review declares phase III bomb - BioWorld MedTech
InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial - insights.citeline.com
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
InflaRx (IFRX) Halts Key Drug Trials, Refocuses Strategy - GuruFocus
InflaRx Halts Vilobelimab Phase 3 Trial for Pyoderma Gangrenosum - TipRanks
InflaRx to Discontinue Vilobelimab Development for Skin Disease Treatment; Shares Down Pre-Bell - marketscreener.com
InflaRx stock plunges on plans to drop lead asset (IFRX:NASDAQ) - Seeking Alpha
InflaRx (IFRX) Halts Phase 3 Trial for Vilobelimab, Shifts Focus - GuruFocus
InflaRx to discontinue vilobelimab indication following IDMC recommendation - TipRanks
InflaRx (IFRX) Halts Phase 3 Trial for Vilobelimab, Shifts Focus | IFRX Stock News - GuruFocus
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum - GlobeNewswire
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum - GlobeNewswire Inc.
InflaRx (NASDAQ:IFRX) Shares Acquired by Northern Trust Corp - Defense World
InflaRx to Participate in Upcoming Investor Conferences - The Manila Times
InflaRx Sets Ambitious Investor Conference Tour: Jefferies, Oppenheimer, and Leerink Partners Ahead - Stock Titan
Cubist Systematic Strategies LLC Makes New Investment in InflaRx (NASDAQ:IFRX) - Defense World
Schonfeld Strategic Advisors LLC Sells 7,756 Shares of InflaRx (NASDAQ:IFRX) - Defense World
Certain Pre-Funded Warrants of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com
Certain Options of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com
Certain Ordinary Shares of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com
Raymond James maintains Strong Buy on Inflarx stock, $13 target By Investing.com - Investing.com Nigeria
Raymond James maintains Strong Buy on Inflarx stock, $13 target - Investing.com
FY2025 EPS Estimates for InflaRx Raised by Cantor Fitzgerald - Defense World
Q2 Earnings Forecast for InflaRx Issued By Leerink Partnrs - Defense World
InflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024) - Yahoo Finance
Oppenheimer Initiates Coverage of InflaRx N.V. (IFRX) with Outperform Recommendation - Nasdaq
This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday - Benzinga
InflaRx N.V. Reports Q1 2025 Financial Results - TipRanks
InflaRx reports Q1 EPS (EUR 0.13) vs (EUR 0.17) last year - TipRanks
InflaRx Reports Q1 2025 Financial Results with Reduced Losses - TipRanks
InflaRx (IFRX) Awaits Key Milestones in Drug Development | IFRX Stock News - GuruFocus
InflaRx N.V. Announces Progress in Toxicology Studies for INF904 and Upcoming Phase 3 Interim Analysis of Vilobelimab - Nasdaq
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
InflaRx NV expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Grows Stake in InflaRx (NASDAQ:IFRX) - Defense World
InflaRx To Reveal Next Month Its Late-Stage Interim Results Of Lead Drug In Painful Ulcer - RTTNews
Cantor Fitzgerald Predicts InflaRx FY2025 Earnings - Defense World
Finanzdaten der Inflarx N V-Aktie (IFRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):